Table 3.
Characteristics of CTDs in 29 patients with lung cancer.
| pSS/sSS (n = 7/n = 2) |
SSc (n = 6) |
SLE (n = 4) |
DM/PM (n = 3/n = 1) |
uCTD (n = 4) |
SV (n = 3) |
PMR (n = 1) |
|
|---|---|---|---|---|---|---|---|
| Male, n (%) | 0 (0) | 0 (0) | 1 (25.0) | 3 (75.0) | 1 (25.0) | 2 (66.7) | 0 (0) |
| Female, n (%) | 7 (77.8) | 6 (100.0) | 3 (75.0) | 1 (25.0) | 3 (75.0) | 1 (33.3) | 1 (100.0) |
| Median age at CTD-years (range) | 57 (44–72) | 39 (27–61) | 55 (41–65) | 67.5 (55–79) | 58 (31–67) | 64 (37–64) | 64 |
| Median age at cancer-years (range) | 58 (50–73) | 55 (43–61) | 59 (41–65) | 67.5 (55–79) | 63 (61–74) | 64 (41–64) | 65 |
| Duration from diagnosis of CTD to LC-years, median (range) | 4 (2–6) | 10 (8–29) | 7 (5–9) | 0 | 10 (7–30) | 2.5 (2–3) | 1 |
| Diagnosed with LC and CTD simultaneusly, n (%) | 3 (33.3) | 1 (16.7) | 2 (50.0) | 4 (100.0) | 1 (25.0) | 1 (33.3) | 0 (0) |
| CTD-ILD, n (%) | 1 (11.1) | 5 (83.3) | 0 (0) | 2 (50.0) | 1 (25.0) | 2 (66.7) | 0 (0) |
| Had smoking history-n (%) | 0 (0) | 0 (0) | 1 (25.0) | 4 (100.0) | 1 (25.0) | 2 (66.7) | 0 (0) |
| Histology of LC, n (%) | |||||||
| AC | 4 (44.4) | 5 (83.3) | 3 (75.0) | 2 (50.0) | 3 (75.0) | 1 (33.3) | 1 (100.0) |
| SC | 1 (11.1) | 1 (16.7) | 1 (25.0) | 0 (0) | 1 (25.0) | 1 (33.3) | 0 (0) |
| SCLC | 0 (0) | 0 (0) | 0 (0) | 2 (50.0) | 0 (0) | 1 (33.3) | 0 (0) |
| NEC-NSC | 2 (22.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| CTD relapsed when LC diagnosed, n (%) | 0 (0) | 2 (33.3) | 0 (0) | 0 (0) | 1 (25.0) | 2 (66.7) | 0 (0) |
| Treatment of CTDs, n (%) | |||||||
| Corticosteroids | 3 (33.3) | 4 (66.7) | 1 (25.0) | 4 (100.0) | 2 (50.0) | 2 (66.7) | 1(100.0) |
| Cyclophosphamide | 0 (0) | 1 (16.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Methotrexate | 0 (0) | 2 (33.3) | 1 (25.0) | 0 (0) | 0 (0) | 2 (66.7) | 0 (0) |
| Others* | 2 (22.2) | 2 (33.3) | 3 (75.0) | 0 (0) | 1 (25.0) | 0 (0) | 0 (0) |
pSS, primary Sjögren’s syndrome; sSS, secondary Sjögren’s syndrome; SSc, systemic sclerosis; SLE, systemic lupus erythematosus; DM/PM, dermatomyositis polymyositis; uCTD, undifferentiated connective tissue disease; SV, systemic vasculitis; PMR, polymyagia rheumatica; CTD-ILD, connective tissue disease-associated interstitial lung disease; AC, adenocarcinoma; SC, squamous carcinoma; SCLC, small cell lung cancer; NEC-NSC, non–small cell neurocrine carcinoma.
* Others: pristimerin, azathioprine, hydroxychloroquine, mycophenolate mofetil, and cyclosporin.